Rho, a CRO, has partnered with Triumph Research Intelligence (TRI), a provider of centralized and risk-based quality management (RBQM) technology. TRI’s RBQM technology platform is designed to optimize trial quality by improving data reliability, patient safety and operational efficiency. Regulatory guidance requiring the adoption of RBQM has led to a rapid increase in demand for centralized and risk-based monitoring solutions from CROs and Sponsors.

“We’re very excited about this collaboration with TRI, as it will enable us to deliver an even better service to our Sponsors,” said Matthew Healy, vice president, Clinical Operations at Rho. “Having a fully validated tool that delivers the entire end-to-end RBQM processes is a key differentiator for us. It means that we can be confident in identifying and documenting potential study risks right from the start, then using the tools we can spot and manage emerging trends, acting much more quickly to target our onsite monitoring activities and focus our efforts on those areas that will improve data quality and better ensure patient safety.”
 
“We’re delighted to be partnering with Rho as they are one of the leading CRO’s with a global reputation for excellence,” said Duncan Hall, chief executive officer and founder of TRI. “In a world of big data, it’s still people that have to make the decisions. Our RBQM technology platform, OPRA, will enable Rho and their Sponsors to make better informed decisions faster, leading to better quality trials and improved patient safety.”